The new COVID-19 oral antiviral medicine nirmatrelvir/ritonavir, better known as PAXLOVID, is now available to be procured through Global Fund support.
The Global Fund Emergency Fund continues supporting eligible applicants sustain the provision and continuity of essential prevention, testing and treatment services for HIV, tuberculosis and malaria during emergency situations.
As part of ongoing ...
A new report by the Global Fund to Fight AIDS, Tuberculosis and Malaria highlights the impact of Global Fund-supported programs to fight HIV, tuberculosis (TB) and malaria over the last 20 years in six Lusophone countries – Guinea-Bissau, Sao Tome a...
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has formally launched the process for selecting its next Chair and Vice-Chair for a 3-year term from 2023-2026, to succeed the current Board Leadership, whose terms expire in May 20...
Application materials for the Global Fund’s 2023-2025 funding cycle are now available on our website, after going through extensive internal and external consultations and alignment with the new 2023-2028 Global Fund Strategy.
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website.
To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.